SCHEMBL11901281

SCHEMBL11901281

C[C@H](NC(=O)OC(C)(C)C)C(=O)Nc1ccccc1NC1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 3/20 0.47
KMT2A Q03164 5/20 0.41
ATM Q13315 1/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
RCE1 Q9Y256 1/20 0.40
MEN1 O00255 3/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
HRH2 P25021 2/20 0.37
HRH1 P35367 2/20 0.37
JAK2 O60674 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13498125 0.92 KMT2A (0.44) AAK1KMT2AATMALDH1A1KDM4E
SCHEMBL11902386 0.88 AAK1 (0.40) AAK1KMT2AATMALDH1A1KDM4E
SCHEMBL11902391 0.88 AAK1 (0.40) AAK1KMT2AATMALDH1A1KDM4E
SCHEMBL12222769 0.79 KMT2A (0.40) AAK1KMT2AATMALDH1A1KDM4E
SCHEMBL11901903 0.78 AAK1 (0.44) AAK1KMT2AATMMEN1HRH2
SCHEMBL2504888 0.78 AAK1 (0.41) AAK1KMT2AATMALDH1A1KDM4E
SCHEMBL2504891 0.78 AAK1 (0.41) AAK1KMT2AATMALDH1A1KDM4E
SCHEMBL2506886 0.77 KMT2A (0.41) AAK1KMT2AATMALDH1A1KDM4E
SCHEMBL12472628 0.77 MAPK1 (0.41) ALDH1A1KDM4ECYP3A4
SCHEMBL2505700 0.77 KDM4E (0.42) AAK1KMT2AATMALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 AAK1 1089/4885KMT2A 4182/4885ATM 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.